FINWIRES · TerminalLIVE
FINWIRES

TYO:4568

16 stories mentioning TYO:4568Updated 12d ago

Every FINWIRES story that references TYO:4568, newest first.

What are analysts saying about TYO:4568?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on TYO:4568?

Asia

Malaysian Blue-Chip Index Ends in Red as Factory Activity Slows in August

Malaysian shares closed slightly lower to end in the red on Monday, as the factory activity growth eased in August.The FTSE Bursa Malaysia KLCI, the main gauge of Malaysian stocks, shed 23.85 points to end 1.4% lower at 1,702.03.Operating conditions across Malaysia's manufacturing sector expanded at a softer pace in August versus the previous month, with the headline S&P Global Malaysia Manufacturing Purchasing Managers' Index (PMI) coming in at 50.2. The latest reading, which provides a gauge of factory sector conditions, compared with the 50.7 recorded in July. A reading above 50 indicates an expansion in sector performance compared to the prior month, while a figure below signals a contraction.In corporate news, shares of Aemulus (KLSE:AEMULUS) slid over 2% on close after its unit Aemulus Corp. secured 14.7 million yuan in new orders from a customer in China for test systems serving the CMOS image sensor market.Shares of HH Healthcare (KLSE:IHH, SGX:Q0F) slid over 1% on Tuesday's close after the Delhi High Court directed the appointment of a forensic auditor in relation to certain applications filed by Daiichi Sankyo (TYO:4568) against the company's unit, Fortis Healthcare (NSE:FORTIS, BOM:532843)

FTSE Bursa Malaysia KLCIBOM:532843KLSE:AEMULUSNSE:FORTISTYO:4568
Asia

IHH Healthcare Provides Update on Indian High Court Order on Case Involving Indian Unit

IHH Healthcare (KLSE:IHH, SGX:Q0F) said the Delhi High Court has directed the appointment of a forensic auditor in relation to certain applications filed by Daiichi Sankyo (TYO:4568) against the company's subsidiary, Fortis Healthcare (NSE:FORTIS, BOM:532843), according to a Tuesday filing with the Singapore Exchange.The order mandates a factual inquiry into the dissipation of the shareholding held by Fortis' promoters, the Singh Brothers, the change in control of Fortis and the role of relevant stakeholders.The court has also directed an examination of a transaction relating to IHH's acquisition of a controlling stake in Fortis through its unit, Northern TK Venture.The court, however, has not imposed any liability, penalty or fine on the healthcare group of Fortis, with the forensic audit being termed as investigative in nature.Earlier, IHH had acquired a 31% stake in Fortis but later halted its open offer for an additional 26% stake after Daiichi had filed a contempt plea against the company's founders.

BOM:532843KLSE:IHHNSE:FORTISSGX:Q0FTYO:4568
Asia

Daiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer

Daiichi Sankyo (TYO:4568) appointed Ken Keller as Chief Commercialization Officer, effective April 1, 2027, in its bid to become a top-five global oncology company by 2035.Keller will lead a new global commercialization unit, centralizing operations to boost efficiency and consistency under the five-year plan, according to a statement on Monday.Keller will retain his board seat at Daiichi Sankyo and continue as chairman, president and CEO of the company's U.S. subsidiary, having joined the company in 2014 and led its global oncology business for the past five years.

TYO:4568
Asia

EU Approves AstraZeneca and Daiichi Sankyo's Datroway for First-Line Triple-Negative Breast Cancer

EU approves AstraZeneca and Daiichi Sankyo's (TYO:4568) Datroway as first-line monotherapy for metastatic triple-negative breast cancer patients ineligible for PD-1/PD-L1 inhibitors, according to a statement on Friday.The decision is based on the TROPION-Breast02 Phase III trial, which demonstrated a 5-month improvement in median overall survival and a 43% reduction in the risk of disease progression or death compared to chemotherapy.This approval makes Datroway the only TROP2-directed antibody drug conjugate in the EU to show an overall survival benefit in this first-line setting, the statement read.The therapy, which was previously approved in the US in May, is now recommended in ESMO Clinical Practice Guidelines as a Category IA treatment option for eligible patients.

TYO:4568
Asia

Daiichi Sankyo's Attributable Profit Slumps 20% in Fiscal Q1

Daiichi Sankyo's (TYO:4568) profit attributable to owners of the company fell 20% to 68.6 billion yen in the fiscal first quarter ended June 30 from 85.50 billion yen a year earlier.The pharmaceutical company's diluted earnings per share declined to 37.70 yen from 46.01 yen a year ago, according to a Friday Japan Exchange filing.Revenue, however, increased 21% to 574.7 billion yen from 474.6 billion yen a year earlier.For the fiscal year ending March 31, 2027, Daiichi Sankyo projected a profit attributable to owners of the company of 251 billion yen, or 137.94 yen per share, with a revenue of 2.34 trillion yen.The company expects to pay a year-end dividend of 50 yen per share, bringing the full-year dividend to 100 yen per share.

TYO:4568
Research

SBI Securities Starts Daiichi Sankyo at Neutral with 2,700 Yen Price Target

Daiichi Sankyo (TYO:4568) has an average rating of buy and mean price target of 4,166 yen, according to analysts polled by FactSet.

TYO:4568
Asia

Daiichi Sankyo Board Approves Treasury Share Disposal Under Medium-Term Share Compensation Plan

Daiichi Sankyo's (TYO:4568) board approved the disposal of 701,100 of its shares worth 1.83 billion yen under its medium-term performance-based share compensation plan.The shares were allocated to Master Trust Bank of Japan for executive compensation, according to a Tuesday filing on the Tokyo Stock Exchange.The disposal will be completed Aug. 6.

TYO:4568
Asia

Daiichi Sankyo Approves 214 Million Yen Treasury Stock Disposal

Daiichi Sankyo (TYO:4568) approved the disposal of 84,081 treasury shares as part of its stock-based remuneration plan.The shares will be allotted at 2,541.5 yen each, resulting in a total value of about 213.7 million yen, according to a company filing on Monday. The shares will be allotted to three directors and 27 corporate officers.

TYO:4568
Asia

Japanese Shares Hit Record Highs After US-Iran Sign Peace Deal

Japanese shares touched a record high on Thursday to close with strong gains after the United States and Iran formally signed a landmark ceasefire agreement on Wednesday.The Nikkei 225 finished the day up 1,151.24 points or 1.65% at 71,053.49.The US and Iran formally signed a ceasefire agreement as Pakistani Prime Minister Shehbaz Sharif confirmed on X that the accord had been electronically signed by the presidents of both nations.Pakistan, who served as mediator, said the deal carries immediate effect, with Iran pledging to reopen the Strait of Hormuz and Washington committing to lift its naval blockade as the first steps under the agreement. This will amount to easing geopolitical conflicts and the cooling of global oil prices.Investors also took into account that they also reacted to the U.S. Federal Reserve holding the interest rates steady. The newly installed Federal Reserve Chair, Kevin Warsh, reaffirmed the Fed's resolve to bring prices back under control, offering no clear signals on what direction policy would take next.Back home, Japan plans to slash its consumption tax to 1% from the current 8%, a first such tax policy shift since the levy was introduced in 1989, Reuters reported Wednesday, citing a proposal submitted to a government panel by ​a senior Liberal Democratic Party executive.On the corporate side, six Japanese confectionery and dairy companies--Morinaga Milk (TYO:2264), Morinaga & Co.(TYO:2201), Akagi Nyugyo, Lotte, Ezaki Glico (TYO:2206), and Meiji (TYO:2269)--are being investigated by the Japan Fair Trade Commission (JFTC) on suspicion of violating the Antimonopoly Act.All six companies confirmed the on-site inspections and pledged full cooperation with authorities, according to statements on their websites on Thursday.Also, Daiichi Sankyo (TYO:4568) entered into a 200 billion yen syndicated, unsecured money loan agreement with Japanese banks. The new borrowing is intended to secure long-term working capital, with repayment scheduled for June 2029 and June 2031, according to a Tokyo bourse filing on Wednesday.

Nikkei 225TYO:2201TYO:2206TYO:2264TYO:2269TYO:4568
Asia

Daiichi Sankyo Secures 200 Billion Yen Loan

Daiichi Sankyo (TYO:4568) entered into a 200 billion yen syndicated, unsecured money loan agreement with Japanese banks.The new borrowing is intended to secure long-term working capital, with repayment scheduled for June 2029 and June 2031, according to a Tokyo bourse filing on Wednesday.Under the covenants, the company must maintain consolidated and non-consolidated net assets at or above 75% of the prior fiscal year-end level.Additionally, starting from the fiscal year ending March 31, 2027, Daiichi Sankyo must avoid reporting a net loss for two consecutive fiscal years.

TYO:4568
Asia

Jefferies Adjusts Daiichi Sankyo's Price Target to 3,600 Yen From 4,600 Yen, Keeps at Buy

Daiichi Sankyo (TYO:4568) has an average rating of buy and mean price target of 4,662.67 yen, according to analysts polled by FactSet.

TYO:4568
Asia

Daiichi Sankyo Delays Release of Fiscal Year 2025 Results to May 11 for Further Review

Daiichi Sankyo (TYO:4568) has rescheduled the announcement of its consolidated financial results for the fiscal year 2025 from April 27 to May 11, citing the need for additional time to finalize figures.The delay is primarily due to a review of supply plans for its oncology portfolio, which requires further deliberation to reasonably estimate loss provisions related to contracts with manufacturers, according to a Tokyo bourse filing on Monday.The company also moved the announcement of its 5-year Business Plan (FY2026-FY2030) from May 19 to align with the new results date on May 11.

TYO:4568
Asia

Japan Shares Rise as as Contained March Inflation Dampens Rate Hike Fears

Japanese shares closed nearly 1% higher on Friday after data showed inflation remained contained in March, reinforcing expectations that the Bank of Japan will refrain from raising interest rates next week.The Nikkei 225 rose nearly 1%, or 575.95 points, to close at 59,716.18.Core consumer prices, excluding fresh food, rose 1.8% year on year in March, matching forecasts and accelerating from 1.6% in February. Energy subsidies continued to limit price pressures despite higher fuel costs linked to Middle East tensions.The data showed energy prices fell 5.7%, a smaller drop than the previous month, while nonperishable food inflation eased. A separate core-core gauge, which strips out energy, rose 2.4%.On the corporate front, Shares of Daiichi Sankyo (TYO:4568) fell about 10% after the company delayed its earnings release and five-year plan while reviewing oncology supply plans, even as it raised its full-year profit outlook on foreign exchange gains.Shares of Renesas Electronics (TYO:6723) dropped about 5% despite reporting a 162% jump in first-quarter profit and strong revenue growth, with the company flagging near-term volatility and issuing only a six-month outlook.Shares of SoftBank Group (TYO:9984) rose 2% after a report said its mobile unit plans to convert part of an Osaka plant into a large-scale battery production site to support AI data centers.

Nikkei 225TYO:4568TYO:6723TYO:9984
Asia

Daiichi Sankyo Raises Full-Year Forecasts on Forex Gains

Daiichi Sankyo (TYO:4568) raised its attributable profit forecast for the fiscal year ended March 31 to 2.5 billion yen from 1.7 billion yen previously, according to a Tokyo bourse filing on Friday.The pharmaceutical firm now expects earnings per share to be 103.26 yen, up from the earlier forecast of 70.16 yen, while the estimate for net sales has been slightly increased to 35.8 billion yen from 35.3 billion yen.The upward revision is primarily driven by a weaker Japanese yen compared with the company's initial assumption of 151 yen per U.S. dollar, resulting in significant foreign exchange gains on foreign currency-denominated assets and liabilities.For the full year, the company recorded total foreign exchange gains of 609 million yen as non-operating income, though this was partially offset by a 227 million yen allowance for doubtful accounts and 301 million yen in derivative valuation losses.Despite these offsets, the company expects ordinary profit to significantly exceed prior forecasts, while the year-end dividend forecast remains unchanged.

TYO:4568
Asia

Daiichi Sankyo Delays Earnings Release Amid Oncology Portfolio Review; Shares Fall 10%

Daiichi Sankyo (TYO:4568) is delaying the release of its consolidated results for the year ended March 31, 2026, to May 11 from April 27 as it requires more time to finalize financial figures, according to a Friday filing on the Tokyo Stock Exchange.Shares of the company plunged nearly 10% in morning trade Friday.The company is reviewing supply plans for its oncology portfolio and development pipeline amid shifting business conditions, which is extending deliberations over estimates for loss provisions tied to contracts with manufacturers.Daiichi Sankyo will also move the release of its five-year business plan for fiscal 2026 through fiscal 2030 to May 11 from May 19 to present both disclosures together for investors.

TYO:4568
Asia

Market Chatter: Suntory Eyes Daiichi Sankyo Healthcare in 200 Billion Yen Deal

Suntory Beverage & Food (TYO:2587) is set to acquire Daiichi Sankyo's (TYO:4568) over-the-counter drug unit for about 200 billion yen as the beverage maker expands its health-related business, Nikkei reported WednesdayThe deal would see Daiichi Sankyo divest its healthcare arm, which produces products such as painkiller Loxonin, stomach medicine Gaster 10 and cold remedy Lulu, according to the report.Suntory is seeking to diversify beyond alcoholic beverages as consumption trends shift, while Daiichi Sankyo is expected to focus resources on prescription drugs amid rising research and development costs, the report said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

TYO:2587TYO:4568

Track with the FINWIRES app suite

FolioX
FolioX
Track TYO:4568 in your portfolio
WheelAI
WheelAI
Analyze TYO:4568 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on TYO:4568